Therapeutic Solutions International (TSOI) S-1/A 7 Feb 23 IPO registration (amended) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2022
Cover [Abstract]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	AMENDMENT FOUR (4)
Entity Registrant Name	Therapeutic Solutions International, Inc.
Entity Central Index Key	0001419051
Entity Primary SIC Number	2833
Entity Tax Identification Number	45-1226465
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	701 Wild Rose Lane
Entity Address, City or Town	Elk City
Entity Address, State or Province	ID
Entity Address, Postal Zip Code	83525
City Area Code	760
Local Phone Number	295-7208
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 94,246	$ 94,036	$ 252,147
Restricted cash	11,003	10,223	10,202
Accounts receivable	42,382	16,613	2,441
Inventory	44,943	39,817	5,399
Prepaid expenses and other current assets	332,015	959,307	77,328
Total current assets	524,589	1,119,996	347,517
Property and equipment, net	354,135	284,024	5,059
Right-of-use asset	15,071	34,184	58,976
Other assets	3,298,465	277,571	191,922
Total assets	4,192,260	1,715,775	603,474
Current liabilities:
Accounts payable	363,984	394,035	302,477
Accounts payable-related parties	7,239	9,791	7,210
Accrued expenses and other current liabilities	552,240	487,208	593,925
Lease liability	12,918	25,374	24,792
Notes payable, current portion	4,638	4,071
Convertible notes payable, net of discount of $210,242, $225,800 and $195,162, at September 30, 2022, December 31, 2021 and 2020, respectively	79,008	79,200	37,338
Notes payable-related parties, net	982,203	965,211	944,098
Derivative liabilities	392,561	531,525	437,549
Total current liabilities	2,394,791	2,496,415	2,347,389
LONG TERM LIABILITIES
Notes payable, net of current portion	11,641	15,532
Lease liability, net of current portion	2,153	8,810	34,184
TOTAL LIABILITIES	2,408,585	2,520,757	2,381,573
Commitments and contingencies
Shareholders’ Deficit:
Preferred stock, $ 0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at September 30, 2022 and December 31, 2021 Respectively
Common stock, $ 0.001 par value; 3,500,000,000 shares authorized; 2,588,063,537, 2,311,123,860 and 2,233,741,391 shares issued and outstanding at September 30, 2022, December 31, 2021 and 2020, respectively.	2,588,064	2,311,125	2,233,742
Additional paid-in capital	15,948,999	10,899,139	7,041,960
Subscription receivable	(21,000)	(21,000)	(21,000)
Accumulated deficit	(16,732,388)	(13,994,246)	(11,032,801)
Total shareholders’ deficit	1,783,675	(804,982)	(1,778,099)
Total liabilities and shareholders’ deficit	$ 4,192,260	$ 1,715,775	$ 603,474

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount, current	$ 210,242	$ 225,800	$ 195,162
Preferred stock, par or stated value per share	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued	2	0
Preferred stock, shares outstanding	2	0
Common stock, par or stated value per share	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	3,500,000,000	3,500,000,000	3,500,000,000
Common stock, shares, issued	2,588,063,537	2,311,123,860	2,233,741,391
Common stock, shares, outstanding	2,588,063,537	2,311,123,860	2,233,741,391

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales	$ 74,541	$ 57,291	$ 198,188	$ 101,796	$ 145,956	$ 62,681
Cost of goods sold	8,790	12,431	33,437	27,598	42,544	12,792
Gross profit	65,751	44,860	164,751	74,198	103,412	49,889
Operating expenses:
General and administrative	204,838	31,271	388,561	96,722	138,710	88,429
Salaries, wages, and related costs	110,108	83,968	336,926	319,198	436,555	849,717
Consulting fees	88,158	107,514	317,284	224,844	264,540	119,209
Legal and professional fees	106,795	492,295	266,158	636,193	773,203	280,124
Research and development	275,071	31,815	1,177,123	183,597	794,750	561,990
Total operating expenses	784,970	746,863	2,486,052	1,460,554	2,407,758	1,899,469
Loss from operations	(719,219)	(702,003)	(2,321,301)	(1,386,356)	(2,304,346)	(1,849,580)
Other income (expense):
Loss on derivative liabilities	(26,867)	(45,006)	(136,583)	(477,559)	(539,006)	(247,620)
Change in fair value of derivative liabilities	(32,205)	53,624	233,303	624,376	494,501	206,501
Interest expense	(167,371)	(121,414)	(512,761)	(399,425)	(611,794)	(302,481)
Other expense						(6,721)
Total other income (expense)	(226,443)	(112,796)	(416,041)	(252,608)	(656,299)	(350,321)
LOSS BEFORE PROVISION FOR INCOME TAXES	(945,662)	(814,799)	(2,737,342)	(1,638,964)	(2,960,645)	(2,199,901)
Provision for income taxes	800		800		800
Net loss	$ (946,462)	$ (814,799)	$ (2,738,142)	$ (1,638,964)	$ (2,961,445)	$ (2,199,901)
Net loss per share - basic and diluted	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Weighted average shares outstanding - basic and diluted	2,565,663,048	2,267,469,428	2,501,116,667	2,253,155,062	2,263,126,970	1,911,855,232

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares To Be Issued [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019		$ 1,614,628	$ 5,183,228			$ (8,832,900)	$ (2,035,044)
Balance, shares at Dec. 31, 2019		1,614,627,811
Common stock issued for services		$ 173,500	496,250				669,750
Common stock issued for services, shares		173,500,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 174,556	88,326				262,882
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares		174,556,025
Relief of derivative liabilities			440,270				440,270
Net loss						(2,199,901)	(2,199,901)
Common stock issued for salaries		$ 78,682	417,218				495,900
Common stock issued for salaries, shares		78,681,818
Common stock sold		$ 192,376	436,124		(21,000)		607,500
Common stock sold, shares		192,375,737
Offering costs			(19,456)				(19,456)
Balance at Dec. 31, 2020		$ 2,233,742	7,041,960		(21,000)	(11,032,801)	(1,778,099)
Balance, shares at Dec. 31, 2020		2,233,741,391
Common stock issued for services		$ 8,500	512,900	36,821			558,221
Common stock issued for services, shares		8,500,000
Common stock issued for prepaid fees		$ 7,500	539,950				547,450
Common stock issued for prepaid fees, shares		7,500,000
Common stock issued for salaries		$ 8,342	231,458				239,800
Common stock issued for accrued salaries, shares		8,341,723
Common stock issued for cash		$ 4,850	280,649				285,499
Common stock issued for cash, shares		4,850,075
Common stock issued for land development		$ 1,500	57,400				58,900
Common stock issued for land development, shares		1,500,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 10,499	292,660				303,159
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares		10,499,263
Relief of derivative liabilities			302,365				302,365
Net loss						(1,638,964)	(1,638,964)
Balance at Sep. 30, 2021		$ 2,274,933	9,259,342	36,821	(21,000)	(12,671,765)	(1,121,669)
Balance, shares at Sep. 30, 2021		2,274,932,452
Balance at Dec. 31, 2020		$ 2,233,742	7,041,960		(21,000)	(11,032,801)	(1,778,099)
Balance, shares at Dec. 31, 2020		2,233,741,391
Common stock issued for services		$ 21,000	837,900				858,900
Common stock issued for services, shares		21,000,000
Common stock issued for prepaid fees		$ 20,000	1,452,450				1,472,450
Common stock issued for prepaid fees, shares		20,000,000
Common stock issued for cash		$ 4,850	280,649				285,499
Common stock issued for cash, shares		4,850,075
Common stock issued for land development		$ 1,500	57,400				58,900
Common stock issued for land development, shares		1,500,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 21,691	508,044				529,735
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares		21,690,671
Relief of derivative liabilities			489,279				489,279
Net loss						(2,961,445)	(2,961,445)
Common stock issued for salaries		$ 8,342	231,457				239,799
Common stock issued for salaries, shares		8,341,723
Balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)	(804,982)
Balance, shares at Dec. 31, 2021		2,311,123,860
Balance at Jun. 30, 2021		$ 2,259,522	8,321,915		(21,000)	(11,856,966)	(1,296,529)
Balance, shares at Jun. 30, 2021		2,259,521,681
Common stock issued for services		$ 5,000	345,000	36,821			386,821
Common stock issued for services, shares		5,000,000
Common stock issued for prepaid fees		$ 4,500	343,450				347,950
Common stock issued for prepaid fees, shares		4,500,000
Common stock issued for salaries		$ 797	40,003				40,800
Common stock issued for accrued salaries, shares		796,875
Common stock issued for cash		$ 1,278	58,722				60,000
Common stock issued for cash, shares		1,278,396
Common stock issued for land development		$ 1,000	34,700				35,700
Common stock issued for land development, shares		1,000,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 2,836	53,874				56,710
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares		2,835,500
Relief of derivative liabilities			61,678				61,678
Net loss						(814,799)	(814,799)
Balance at Sep. 30, 2021		$ 2,274,933	9,259,342	36,821	(21,000)	(12,671,765)	(1,121,669)
Balance, shares at Sep. 30, 2021		2,274,932,452
Balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)	(804,982)
Balance, shares at Dec. 31, 2021		2,311,123,860
Common stock issued for services		$ 25,303	482,775				508,078
Common stock issued for services, shares		25,302,577
Common stock issued for prepaid fees		$ 11,000	231,320				242,320
Common stock issued for prepaid fees, shares		11,000,000
Common stock issued for salaries		$ 1,034	28,965				29,999
Common stock issued for accrued salaries, shares		1,034,482
Common stock issued for cash		$ 44,500	400,500				445,000
Common stock issued for cash, shares		44,500,000
Common stock issued for land development		$ 4,000	46,400				50,400
Common stock issued for land development, shares		4,000,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 41,700	901,732				943,432
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares		41,700,228
Relief of derivative liabilities
Net loss						(2,738,142)	(2,738,142)
Common stock issued for license		$ 149,402	2,958,168				3,107,570
Common stock issued for license, shares		149,402,390
Issuance of preferred stock
Issuance of preferred stock, shares	2
Balance at Sep. 30, 2022		$ 2,588,064	15,948,999		(21,000)	(16,732,388)	1,783,675
Balance, shares at Sep. 30, 2022	2	2,588,063,537
Balance at Jun. 30, 2022		$ 2,552,228	15,467,138		(21,000)	(15,785,926)	2,212,440
Balance, shares at Jun. 30, 2022		2,552,228,460
Common stock issued for services		$ 9,303	91,575				100,878
Common stock issued for services, shares		9,302,577
Common stock issued for prepaid fees		$ 5,000	88,500				93,500
Common stock issued for prepaid fees, shares		5,000,000
Common stock issued for land development		$ 4,000	46,400				50,400
Common stock issued for land development, shares
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 17,533	255,386				272,919
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares		17,532,500
Net loss						(946,462)	(946,462)
Issuance of preferred stock
Issuance of preferred stock, shares	2
Balance at Sep. 30, 2022		$ 2,588,064	$ 15,948,999		$ (21,000)	$ (16,732,388)	$ 1,783,675
Balance, shares at Sep. 30, 2022	2	2,588,063,537

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended		60 Months Ended	69 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (946,462)	$ (814,799)	$ (2,738,142)	$ (1,638,964)	$ (2,961,445)	$ (2,199,901)	$ 14,200,000	$ 16,700,000
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to consultants			311,078	416,321	397,750	100,600
Stock-based compensation to related parties			197,000	141,900	461,150	1,065,050
Loss on derivative liabilities	26,867	45,006	136,583	477,559	539,006	247,620
Change in fair value of derivative liabilities	32,205	(53,624)	(233,303)	(624,376)	(494,501)	(206,501)
Gain on extinguishment of debt						(16,479)
Amortization of prepaid stock-based compensation			868,089	91,646	480,135
Amortization of debt discount			461,058	353,320	541,612	251,801
Patent amortization			191,192	4,943	11,295	6,591
Depreciation			3,489	4,051	6,772	389
Changes in operating assets and liabilities:
Accounts receivable			(25,769)	(19,047)	(14,172)	463
Inventory			(5,126)	(56,005)	(34,418)	(219)
Prepaid expenses and other current assets			73,807	88,789	64,777	(15,140)
Right-of-use asset			19,113	18,531	24,792	(53,357)
Accounts payable			(30,051)	59,178	91,557	(22,458)
Accounts payable - related parties			(2,552)	42	2,581	(5,505)
Accrued expenses and other current liabilities			139,405	132,549	188,979	130,611
Lease liability			(19,113)	(18,531)	(24,792)	53,356
Net cash used in operating activities			(653,242)	(568,094)	(718,922)	(663,079)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment				(260,565)	(260,565)	(5,448)
Purchase of license			(200,000)
Deposits				4,015	4,015
Net cash used in investing activities			(200,000)	(256,550)	(256,550)	(5,448)
Cash flows from financing activities
Payments on notes payable to related party			(2,444)	(3,503)	(4,799)	(25,244)
Proceeds from convertible notes payable			415,000	353,750	538,750	315,000
Proceeds from notes payable						16,479
Payments on notes payable			(3,324)	(969)	(2,068)
Proceeds from sale of common stock			445,000	285,499	285,499	588,044
Net cash provided by financing activities			854,232	634,777	817,382	894,279
Net increase (decrease) in cash, cash equivalents and restricted cash			990	(189,867)	(158,090)	225,752
Cash, cash equivalents and restricted cash at beginning of year			104,259	262,349	262,349	36,597
Cash, cash equivalents and restricted cash at end of year	105,249	72,482	105,249	72,482	104,259	262,349	104,259	105,249
Supplemental cash flow information:
Cash paid for interest			2,357	2,311	3,312	6,369
Cash paid for income taxes			800	800	800	1,585
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable			30,500	22,250	33,500	21,500
Debt discount recorded in connection with derivative liability			415,000	353,750	538,750	315,000
Common stock issued in conversion of convertible notes payable and interest			943,431	605,525	1,019,014	713,152
Property and equipment purchased with note payable				21,671	21,671
Common stock issued for prepaid fees			242,320	547,450	1,472,450
Common stock issued for accrued salaries			29,999	239,800	239,799
Accrued interest added to principal			19,436	19,434	25,912	26,876
Common stock issued for license			3,107,570
Common stock issued for land development			50,400	58,900	58,900
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	94,246	62,259	94,246	62,259	94,036	252,147	94,036	94,246
Restricted cash	11,003	10,223	11,003	10,223	10,223	10,202	10,223	11,003
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:	$ 105,249	$ 72,482	$ 105,249	$ 72,482	$ 104,259	$ 262,349	$ 104,259	$ 105,249

Organization and Business Descr

Organization and Business Description	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Description	Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Business Description Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health. Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Management does not expect existing cash as of September 30, 2022, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of September 30, 2022, the Company has incurred losses totaling $ 16.7	Note 1 – Nature of business Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91% In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. Management does not expect existing cash as of December 31, 2021, or as of March 31, 2022, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2021, the Company has incurred losses totaling $ 14.2 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021

Basis of presentation and signi

Basis of presentation and significant accounting policies	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of presentation and significant accounting policies	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 392,561 531,525 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2022 and December 31, 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the nine months ended September 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 576,592 Conversions (482,253 ) Change in fair market value of derivative liabilities (233,303 ) Balance, September 30, 2022 $ 392,561 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of September 30, 2022 and 2021, a total of 211,919,728 286,251,995 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2022, and 2021 was $ 3,489 and $ 4,051 , respectively. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2022, and 2021 was $ 191,192 and $ 4,943 , respectively. Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,177,123 and $ 183,597 for the nine months ended September 30, 2022, and 2021, respectively. Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018, for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 15,071 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retai Inspection of Goods & Rejection. Risk of Loss. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Retail policies of e-commerce: Returns. Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 12,349 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2021 and 2020, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 531,525 437,549 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2021 and 2020: Schedule of Change in Derivative Liability Balance, December 31, 2019 $ 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270 ) Change in fair market value of derivative liabilities (206,501 ) Balance, December 31, 2020 437,549 Issuance of new derivative liabilities 1,077,756 Conversions to paid-in capital (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 $ 531,525 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2021, and 2020, a total of 95,273,690 and 579,347,525 , respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2021, and 2020 was $ 6,772 and $ 389 , respectively. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2021, and 2020 was $ 11,295 6,591 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 794,750 and $ 561,990 for the years ended December 31, 2021, and 2020, respectively. Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 34,184 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Restricted cash

Restricted cash	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Restricted cash	Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6 This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011	Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6 This certificate matures on June 17, 2022 and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011

Prepaid expense and other curre

Prepaid expense and other current assets	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expense And Other Current Assets
Prepaid expense and other current assets	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 239,646 $ 930,893 Insurance 1,717 987 Prepaid costs 90,652 27,427 Total $ 332,015 $ 959,307 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 930,893 $ 76,663 Insurance 987 665 Prepaid costs 27,427 - Total $ 959,307 $ 77,328 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021

Fixed assets

Fixed assets	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Fixed assets	Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets September 30, 2022 December 31, 2021 Land $ 308,823 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 374,959 301,159 Accumulated depreciation (20,824 ) (17,135 ) Property and equipment, net $ 354,135 $ 284,024 Depreciation expense was $ 3,489 and $ 4,051 for the nine months ended September 30, 2022, and 2021, respectively.	Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2021 December 31, 2020 Land $ 235,223 $ - Vehicles 50,514 - Computer hardware 5,935 10,747 Office furniture and equipment 7,912 3,639 Shipping and other equipment 1,575 7,023 Total 301,159 21,409 Accumulated depreciation (17,135 ) (16,350 ) Property and equipment, net $ 284,024 $ 5,059 Depreciation expense was $ 6,772 and $ 389 for the years ended December 31, 2021, and 2020, respectively. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021

Other assets

Other assets	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other assets	Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 13,189 $ 108,673 Deposit 39,823 39,823 Regulatory assets/Patent rights 200,000 - Licenses, net 3,045,453 129,075 Total $ 3,298,465 $ 277,571 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on 9/15/2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390 0.0208 3,107,570 December 31, 2032 10 five years 200,000 1.8 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses September 30, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (215,669 ) (24,477 ) Licenses, net $ 3,045,453 $ 129,075 Amortization expense for the nine months ended September 30, 2022 and 2021 was $ 191,192 4,943	Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 108,673 $ 39,914 Deposit 39,823 11,638 Licenses, net 129,075 140,370 Total $ 277,571 $ 191,922 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2021 December 31, 2020 License $ 153,552 $ 153,552 Accumulated amortization (24,477 ) (13,182 ) Licenses, net $ 129,075 $ 140,370 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021

Notes Payable-Related Party

Notes Payable-Related Party	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable-Related Party	Note 7 - Notes Payable-Related Party At September 30, 2022 and December 31, 2021, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $ 982,203 and $965,211 , respectively. Interest accrued on these notes during the nine months ended September 30, 2022, and 2021 was $ 12,956 and $ 12,956 , respectively. Of these, $ 251,000 are convertible into common stock at prices ranging from $ 0.004 and $ 0.005 . Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2021 December 31, 2020 $ 2,356 $ 7,054 $ 2,356 $ 7,054 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ 2,356 $ 7,054 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 27,577 26,064 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,544 534,646 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 118,400 112,000 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 282,334 264,334 965,211 944,098 Less debt discount - - $ 965,211 $ 944,098	Note 8 – Notes payable-related parties Notes Payable-Related Party Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2021 December 31, 2020 $ 2,356 $ 7,054 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ 2,356 $ 7,054 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 27,577 26,064 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,544 534,646 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 118,400 112,000 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 282,334 264,334 965,211 944,098 Less debt discount - - $ 965,211 $ 944,098

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable At various times during the nine months ended September 30, 2022, the Company entered into convertible promissory notes with principal amounts totaling $ 445,500 415,000 30,500 10 12 January 1, 2023 to September 27, 2023 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% 224,973,061 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the nine months ended September 30, 2022, the Company valued the conversion feature on the date of issuance resulting in an initial liability of $ 576,592 161,592 0.0064 0.0143 0.0153 0.0272 0 148 216 0.48 4.16 one year THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 During the nine months ended September 30, 2022, convertible notes with principal and accrued interest balances totaling $ 620,051 41,700,228 25,009 0.0063 0.016 0.010 0.026 0 63 191 0.51 4.08 0.44 0.50 On September 30, 2022, the derivative liabilities on the remaining convertible notes were revalued at $ 392,561 resulting in a gain of $ 233,303 for the nine months ended September 30, 2022, related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise prices of $ 0.0064 , the closing stock price of the Company’s common stock on the date of valuation of $ 0.013 , an expected dividend yield of 0 %, expected volatility ranging from 92 % to 158 %, risk-free interest rate of 4.05 %, and an expected term ranging from 0.52 to 0.99 years. The Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to the effective interest method. During the nine months ended September 30, 2022, and 2021, the Company amortized $ 461,058 and $ 353,320 to interest expense, respectively. As of September 30, 2022, discounts of $ 210,242 remained which will be amortized through September 2023 .	Note 7 – Convertible notes payable Convertible Notes Payable At various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts totaling $ 572,250 with third parties for which the proceeds were used for operations. The Company received net proceeds of $ 538,750 , and a $ 33,500 original issuance discount was recorded. The convertible promissory notes incur interest at rates ranging from 10 % to 12 % per annum and mature on dates ranging from January 25, 2022, to December 15, 2022 . The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% . The Company was required to reserve at December 31, 2021 a total of 95,273,690 common shares in connection with these promissory notes. On various dates throughout the year ended December 31, 2020, the Company entered into seven convertible promissory notes with principal amounts totaling $ 336,500 with a third party for which the proceeds were used for operations. The Company received net proceeds of $ 315,000 , and a $ 21,500 original issuance discount was recorded. The convertible promissory notes incur interest at 12 % per annum and mature on dates ranging from February 3, 2021, to December 17, 2021 . The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 61% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% . The Company was required to reserve at December 31, 2020 a total of 579,347,525 common shares in connection with these promissory notes. Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 7 – Convertible notes payable (Continued) For the seven notes issued during the year ended December 31, 2020, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 562,620 247,620 0.0008 0.0042 0.0023 0.0056 0 237 260 0.17 1.48 one year During the year ended December 31, 2020, convertible notes principal plus their accrued interest totaling $ 262,882 174,556,025 440,270 0.00055 0.0039 0.001 0.010 0 170 305 0.12 0.89 0.07 0.50 On December 31, 2020, the derivative liabilities on the remaining four convertible notes were revalued at $ 437,539 resulting in a gain of $ 206,501 for the year ended December 31, 2020, related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $ 0.0029 , the closing stock price of the Company’s common stock on the date of valuation of $ 0.0064 , an expected dividend yield of 0 %, expected volatility ranging from 241 % to 254 %, risk-free interest rate of 0.12 %, and an expected term ranging from 0.76 to 0.96 years. For the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 1,077,756 539,006 0.0039 0.0351 0.0217 0.0540 0 197 264 0.05 0.29 one year During the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $ 529,735 21,690,671 489,279 0.0136 0.035 0.022 0.057 0 125 251 0.06 0.29 0.48 0.50 On December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $ 531,525 resulting in a gain of $ 494,501 for the year ended December 31, 2021, related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $ 0.0123 to $ 0.0127 , the closing stock price of the Company’s common stock on the date of valuation of $ 0.029 , an expected dividend yield of 0 %, expected volatility ranging from 165 % to 218 %, risk-free interest rate of 0.39 %, and an expected term ranging from 0.53 to 0.96 years. The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2021, and 2020, the Company amortized $ 541,612 and $ 251,801 to interest expense, respectively. As of December 31, 2021, discounts of $ 225,800 remained for which will be amortized through December 2022. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021

Equity

Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Equity	Note 9 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 3,500,000,000 0.001 5,000,000 2,588,063,537 2 In 2021, we issued 4,850,075 285,500 In 2021, we issued 21,000,000 858,900 In 2021, we issued 8,341,723 239,799 In 2021, we issued 1,500,000 58,900 In 2021, we issued 21,690,671 1,019,014 In 2022, we issued 44,500,000 445,000 In 2022, we issued 25,302,577 508,078 In 2022, we issued 1,034,482 29,999 In 2022, we issued 149,402,390 3,107,570 In 2022, we issued 41,700,228 595,042 In 2022, we issued 11,000,000 242,320 In 2022, we issued 4,000,000 50,400 On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class. On August 9, 2022, we issued 2 0.001 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022	Note 11 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 3,500,000,000 0.001 5,000,000 2,311,123,860 no In 2020, we issued 192,375,737 607,500 In 2020, we issued 173,500,000 669,750 In 2020, we issued 78,681,818 495,900 In 2020, we issued 174,556,025 703,152 In 2021, we issued 4,850,075 285,500 In 2021, we issued 21,000,000 858,900 In 2021, we issued 8,341,723 239,799 In 2021, we issued 1,500,000 58,900 In 2021, we issued 21,690,671 1,019,014 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021

Related party transactions

Related party transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Related party transactions	Note 9 – Related party transactions As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $ 439,534 and $ 663,100 , respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t accrue interest and will be paid as 0.5 % of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2021 and 2020.	Note 9 – Related party transactions As of December 31, 2019, and 2018, the Company had accrued officers’ salary of $ 439,534 and $ 663,100 , respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019, and doesn’t accrue interest and will be paid as 0.5 % of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2021, and 2020. In 2020, the Company settled an accrual of wages with Timothy G. Dixon with a convertible note payable of $ 60,000 5 18,181,818 60,000 In 2020 we issued 122,000,000 437,400 In 2020 we issued 29,000,000 240,000 On June 15, 2020, we issued 20,000,000 106,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 9 – Related party transactions (continued) On July 17, 2020, we issued 22,500,000 shares of common stock to two officers, and one director of the Company under a Restricted Stock Award for $ 154,500 . In 2021, we issued 7,544,848 shares of common stock for $ 239,800 of accrued salaries to one officer of the Company under a Restricted Stock Award. On June 18, 2021, we issued 2,000,000 94,600 On November 30, 2021, we issued 7,000,000 224,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021

Income taxes

Income taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income taxes	Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30 Schedule of Income tax Expense December 31, 2021 December 31, 2020 Expected income tax at statutory rate $ (621,735 ) $ (458,619 ) State tax 168 168 Meals & Entertainments 295 - Permanent differences 404,577 295,578 Other (71,992 ) (336 ) Change in valuation allowance 289,487 163,209 Provision for income taxes $ 800 $ - The significant components of deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Net operating loss carry-forward $ 1,450,896 $ 1,668,324 Valuation allowance (1,450,896 ) (1,668,324 ) Net deferred tax asset $ - $ - The Company has Federal net operating loss carryforwards of approximately $ 7.5 6.5 5.5 4.5 5 expires beginning in fiscal 2032 As of and for the years ended December 31, 2021 and 2020, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2021 and 2020. The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2018. The Company currently is not under examination by any tax authority.	Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30 Schedule of Income tax Expense December 31, 2021 December 31, 2020 Expected income tax at statutory rate $ (621,735 ) $ (458,619 ) State tax 168 168 Meals & Entertainments 295 - Permanent differences 404,577 295,578 Other (71,992 ) (336 ) Change in valuation allowance 289,487 163,209 Provision for income taxes $ 800 $ - The significant components of deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Net operating loss carry-forward $ 1,450,896 $ 1,668,324 Valuation allowance (1,450,896 ) (1,668,324 ) Net deferred tax asset $ - $ - The Company has Federal net operating loss carryforwards of approximately $ 7.5 million and $ 6.5 million as of December 31, 2021, and 2020, respectively. The Company has state net operating loss carryforwards of approximately $ 5.5 million and $ 4.5 million as of December 31, 2021, and 2020, respectively. The net operating loss carryforwards are available to offset taxable income in future years, of which approximately $ 5 million expires beginning in fiscal 2032 . Net operating loss carry forwards incurred after 2018 are carried on indefinitely. As of and for the years ended December 31, 2021, and 2020, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2021 and 2020. The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2018. The Company currently is not under examination by any tax authority.

Legal proceedings

Legal proceedings	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Legal Proceedings
Legal proceedings	Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.	Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Subsequent events

Subsequent events	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent events	Note 10 – Subsequent events On October 5, 2022, we issued 110,000 .0122 On October 7, 2022, we issued 5,322,581 33,000 On October 11, 2022, we issued 8,014,113 49,687.50 On November 2, 2022, we issued 3,000,000 .0099 On November 2, 2022, we issued 3,777,777 .0099 In accordance with ASC 855, the Company has analyzed its operations subsequent to November 17, 2022, through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.	Note 14 – Subsequent events On January 4, 2022, we issued 1,034,482 30,000 On January 14, 2022,we issued 4,158,759 56,975 On February, 2022, we issued 4,778,689 58,300 On February 14, 2022, we issued 24,500,000 0.01 On February 24, 2022, we issued 10,000,000 0.01 On February 24, 2022, we issued 149,402,390 15,000,000 In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2021, through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 36 April 30, 2023 Total rent expense for the nine months is $ 18,783 The lease will expire in 2023 5 Future minimum lease payments as of December 31, 2022, are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2022 $ 6,249 2023 $ 8,612 As of March 25, 2022, we entered into an asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is for five years . The Company has made an initial payment of $ 200,000 . Within six months, the Company will make a second payment of $ 1.8 million. The Company has not made the payment yet. This has not affected the agreement.	Note 13 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 36 April 30, 2023 During the year ended December 31, 2021 and 2020, the Company incurred rent expense of $ 22,768 25,993 The lease will expire in 2023. The weighted average discount rate used for this lease is 5 Schedule of Future Minimum Lease Payments 2022 26,460 2023 8,911 Total lease payment 35,371 Less: Imputed Interest (1,187 ) Present value of lease liabilities 34,184 Current portion (25,374 ) Non-current portion 8,810 Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

Basis of presentation and sig_2

Basis of presentation and significant accounting policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock.	Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retai Inspection of Goods & Rejection. Risk of Loss. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Retail policies of e-commerce: Returns. Shipping. Out of Stock.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 12,349
Inventories	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 392,561 531,525	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2021 and 2020, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 531,525 437,549
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2022 and December 31, 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the nine months ended September 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 576,592 Conversions (482,253 ) Change in fair market value of derivative liabilities (233,303 ) Balance, September 30, 2022 $ 392,561	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2021 and 2020: Schedule of Change in Derivative Liability Balance, December 31, 2019 $ 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270 ) Change in fair market value of derivative liabilities (206,501 ) Balance, December 31, 2020 437,549 Issuance of new derivative liabilities 1,077,756 Conversions to paid-in capital (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 $ 531,525
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of September 30, 2022 and 2021, a total of 211,919,728 286,251,995	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2021, and 2020, a total of 95,273,690 and 579,347,525 , respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued)
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2022, and 2021 was $ 3,489 and $ 4,051 , respectively.
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2022, and 2021 was $ 191,192 and $ 4,943 , respectively.	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2021, and 2020 was $ 11,295 6,591
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,177,123 and $ 183,597 for the nine months ended September 30, 2022, and 2021, respectively.	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 794,750 and $ 561,990 for the years ended December 31, 2021, and 2020, respectively.
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”	Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018, for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.
Leases	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 15,071	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 34,184 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued)
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.	Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.
Principles of Consolidation		Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.
Depreciation and Amortization		Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2021, and 2020 was $ 6,772 and $ 389 , respectively.

Basis of presentation and sig_3

Basis of presentation and significant accounting policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Change in Derivative Liability	The following is the change in derivative liability for the nine months ended September 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 576,592 Conversions (482,253 ) Change in fair market value of derivative liabilities (233,303 ) Balance, September 30, 2022 $ 392,561	The following is the change in derivative liability for the years ended December 31, 2021 and 2020: Schedule of Change in Derivative Liability Balance, December 31, 2019 $ 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270 ) Change in fair market value of derivative liabilities (206,501 ) Balance, December 31, 2020 437,549 Issuance of new derivative liabilities 1,077,756 Conversions to paid-in capital (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 $ 531,525

Prepaid expense and other cur_2

Prepaid expense and other current assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expense And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 239,646 $ 930,893 Insurance 1,717 987 Prepaid costs 90,652 27,427 Total $ 332,015 $ 959,307	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 930,893 $ 76,663 Insurance 987 665 Prepaid costs 27,427 - Total $ 959,307 $ 77,328

Fixed assets (Tables)

Fixed assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following: Schedule of Fixed Assets September 30, 2022 December 31, 2021 Land $ 308,823 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 374,959 301,159 Accumulated depreciation (20,824 ) (17,135 ) Property and equipment, net $ 354,135 $ 284,024	Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2021 December 31, 2020 Land $ 235,223 $ - Vehicles 50,514 - Computer hardware 5,935 10,747 Office furniture and equipment 7,912 3,639 Shipping and other equipment 1,575 7,023 Total 301,159 21,409 Accumulated depreciation (17,135 ) (16,350 ) Property and equipment, net $ 284,024 $ 5,059

Other assets (Tables)

Other assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consist of the following: Schedule of Other Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 13,189 $ 108,673 Deposit 39,823 39,823 Regulatory assets/Patent rights 200,000 - Licenses, net 3,045,453 129,075 Total $ 3,298,465 $ 277,571	Other assets consist of the following: Schedule of Other Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 108,673 $ 39,914 Deposit 39,823 11,638 Licenses, net 129,075 140,370 Total $ 277,571 $ 191,922
Schedule of Net Licenses	Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses September 30, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (215,669 ) (24,477 ) Licenses, net $ 3,045,453 $ 129,075	Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2021 December 31, 2020 License $ 153,552 $ 153,552 Accumulated amortization (24,477 ) (13,182 ) Licenses, net $ 129,075 $ 140,370

Notes Payable-Related Party (Ta

Notes Payable-Related Party (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable Related Parties	Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2021 December 31, 2020 $ 2,356 $ 7,054 $ 2,356 $ 7,054 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ 2,356 $ 7,054 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 27,577 26,064 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,544 534,646 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 118,400 112,000 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 282,334 264,334 965,211 944,098 Less debt discount - - $ 965,211 $ 944,098	Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2021 December 31, 2020 $ 2,356 $ 7,054 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ 2,356 $ 7,054 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 27,577 26,064 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,544 534,646 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 118,400 112,000 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 282,334 264,334 965,211 944,098 Less debt discount - - $ 965,211 $ 944,098

Income taxes (Tables)

Income taxes (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income tax Expense	Schedule of Income tax Expense December 31, 2021 December 31, 2020 Expected income tax at statutory rate $ (621,735 ) $ (458,619 ) State tax 168 168 Meals & Entertainments 295 - Permanent differences 404,577 295,578 Other (71,992 ) (336 ) Change in valuation allowance 289,487 163,209 Provision for income taxes $ 800 $ -	Schedule of Income tax Expense December 31, 2021 December 31, 2020 Expected income tax at statutory rate $ (621,735 ) $ (458,619 ) State tax 168 168 Meals & Entertainments 295 - Permanent differences 404,577 295,578 Other (71,992 ) (336 ) Change in valuation allowance 289,487 163,209 Provision for income taxes $ 800 $ -
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Net operating loss carry-forward $ 1,450,896 $ 1,668,324 Valuation allowance (1,450,896 ) (1,668,324 ) Net deferred tax asset $ - $ -	The significant components of deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Net operating loss carry-forward $ 1,450,896 $ 1,668,324 Valuation allowance (1,450,896 ) (1,668,324 ) Net deferred tax asset $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of December 31, 2022, are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2022 $ 6,249 2023 $ 8,612	Schedule of Future Minimum Lease Payments 2022 26,460 2023 8,911 Total lease payment 35,371 Less: Imputed Interest (1,187 ) Present value of lease liabilities 34,184 Current portion (25,374 ) Non-current portion 8,810

Organization and Business Des_2

Organization and Business Description (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended		60 Months Ended	69 Months Ended
	Aug. 04, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation date				Aug. 06, 2007		Aug. 06, 2007
Net loss		$ (946,462)	$ (814,799)	$ (2,738,142)	$ (1,638,964)	$ (2,961,445)	$ (2,199,901)	$ 14,200,000	$ 16,700,000
Unusual or infrequent item, description	the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%

Schedule of Change in Derivativ

Schedule of Change in Derivative Liability (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Beginning Balance	$ 531,525	$ 437,549	$ 521,700
Issuance of new derivative liabilities	576,592	1,077,756	562,620
Conversions to paid-in capital	(482,253)	(489,279)	(440,270)
Change in fair market value of derivative liabilities	(233,303)	(494,501)	(206,501)
Ending Balance	$ 392,561	$ 531,525	$ 437,549

Basis of presentation and sig_4

Basis of presentation and significant accounting policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Payments description			Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail		Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retai
Cash, FDIC insured amount	$ 0	$ 0	$ 0	$ 0	$ 0	$ 12,349
Derivative liabilities	392,561		$ 392,561		$ 531,525	$ 437,549
Antidilutive securities excluded from computation of earnings per share			211,919,728	286,251,995	95,273,690	579,347,525
Depreciation			$ 3,489	$ 4,051	$ 6,772	$ 389
Amortization expense			191,192	4,943	11,295	6,591
Research and Development Expense	275,071	$ 31,815	1,177,123	$ 183,597	794,750	561,990
Right-of-use asset	15,071		15,071		34,184	58,976
Lease liability	15,071		15,071		$ 34,184
Maximum [Member]
Property, Plant and Equipment [Line Items]
Cash, FDIC insured amount	$ 250,000		$ 250,000			$ 250,000

Restricted cash (Details Narrat

Restricted cash (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Restricted cash and non-cash equivalents	$ 10,000	$ 10,000
Annual interest rate	0.60%	0.60%
Restricted cash description	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011	This certificate matures on June 17, 2022 and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expense And Other Current Assets
Prepaid consulting	$ 239,646	$ 930,893	$ 76,663
Insurance	1,717	987	665
Prepaid costs	90,652	27,427
Total	$ 332,015	$ 959,307	$ 77,328

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total	$ 374,959	$ 301,159	$ 21,409
Accumulated depreciation	(20,824)	(17,135)	(16,350)
Property and equipment, net	354,135	284,024	5,059
Land [Member]
Property, Plant and Equipment [Line Items]
Total	308,823	235,223
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	50,514	50,514
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	6,135	5,935	10,747
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	7,912	7,912	3,639
Shipping and Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,575	$ 1,575	$ 7,023

Fixed assets (Details Narrative

Fixed assets (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 3,489	$ 4,051	$ 6,772	$ 389

Schedule of Other Assets (Detai

Schedule of Other Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid consulting	$ 13,189	$ 108,673	$ 39,914
Deposit	39,823	39,823	11,638
Regulatory assets/Patent rights	200,000
Licenses, net	3,045,453	129,075	140,370
Total	$ 3,298,465	$ 277,571	$ 191,922

Schedule of Net Licenses (Detai

Schedule of Net Licenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
License	$ 3,261,122	$ 153,552	$ 153,552
Accumulated amortization	(215,669)	(24,477)	(13,182)
Licenses, net	$ 3,045,453	$ 129,075	$ 140,370

Other assets (Details Narrative

Other assets (Details Narrative) - USD ($)			3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 25, 2022	Feb. 23, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Number of shares issuance value			$ 60,000	$ 445,000	$ 285,499	$ 285,499
Payment to acquire license				200,000
Amortization of intangible assets				$ 191,192	$ 4,943	$ 11,295	$ 6,591
Common Stock [Member]
Number of shares issuance			1,278,396	44,500,000	4,850,075	4,850,075
Number of shares issuance value			$ 1,278	$ 44,500	$ 4,850	$ 4,850
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member]
Patent expires agreement date		Dec. 31, 2032
Amortized useful life		10 years
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member] | Common Stock [Member]
Number of shares issuance		149,402,390
Share price		$ 0.0208
Number of shares issuance value		$ 3,107,570
Assets Transfer and License Agreement [Member]
Amortized life of agreement	5 years
Assets Transfer and License Agreement [Member] | Initial Payment [Member]
Payment to acquire license	$ 200,000
Assets Transfer and License Agreement [Member] | Second Payment [Member]
Payment to acquire license	$ 1,800,000

Schedule of Notes Payable Relat

Schedule of Notes Payable Related Parties (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Short-Term Debt [Line Items]
Notes payable related party, current	$ 982,203	$ 965,211	$ 944,098
Less debt discount
Notes payable related party, non-current		965,211	944,098
Notes Payable One [Member]
Short-Term Debt [Line Items]
Notes payable related party, current		2,356	7,054
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable related party, current		27,577	26,064
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Notes payable related party, current		534,544	534,646
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes payable related party, current		118,400	112,000
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Notes payable related party, current		$ 282,334	$ 264,334

Schedule of Notes Payable Rel_2

Schedule of Notes Payable Related Parties (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2021 $ / shares
Chief Financial Officer [Member]
Short-Term Debt [Line Items]
Debt interest percentage	8%
Debt maturity date	Dec. 31, 2019
Scientific Advisory Board [Member]
Short-Term Debt [Line Items]
Debt interest percentage	10%
Debt maturity date	Dec. 31, 2019
Scientific Advisory Board [Member] | Notes Payable One [Member]
Short-Term Debt [Line Items]
Debt interest percentage	10%
Scientific Advisory Board [Member] | Notes Payable Three [Member]
Short-Term Debt [Line Items]
Debt interest percentage	10%
Chief Executive Officer [Member] | Notes Payable One [Member]
Short-Term Debt [Line Items]
Debt interest percentage	8%
Business Advisory Board [Member]
Short-Term Debt [Line Items]
Debt maturity date	Apr. 20, 2019
Business Advisory Board [Member] | Notes Payable One [Member]
Short-Term Debt [Line Items]
Debt interest percentage	8%
Share price	$ 0.005
Business Advisory Board [Member] | Notes Payable Two [Member]
Short-Term Debt [Line Items]
Debt interest percentage	10%
Share price	$ 0.004

Notes Payable-Related Party (De

Notes Payable-Related Party (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Notes Payable, Related Parties, Current	$ 982,203	$ 965,211		$ 944,098
Officers and Directors [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties, Current	982,203	$ 965,211
Interest Payable, Current	12,956		$ 12,956
Debt Conversion, Converted Instrument, Amount	$ 251,000
Officers and Directors [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 0.004
Officers and Directors [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 0.005

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 30, 2021	Dec. 30, 2020 $ / shares
Debt Instrument [Line Items]
Proceeds from convertible debt			$ 415,000	$ 353,750	$ 538,750	$ 315,000
Debt discount
Derivative Liability	$ 392,561		392,561		531,525	437,549
Interest Expense	167,371	$ 121,414	512,761	399,425	611,794	302,481
Loss on derivative liability	26,867	$ 45,006	136,583	477,559	539,006	247,620
Additional paid in capital on convertible debt features					489,279
Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative issuance liability						562,620
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount	210,242		$ 210,242		225,800
Debt maturity date description			amortized through September 2023
Interest Expense			$ 461,058	$ 353,320
Interest Expense, Debt					$ 541,612	$ 251,801
Measurement Input, Expected Term [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term					1 year
Measurement Input, Expected Term [Member] | Convertible Notes Payable [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term						1 year
Derivative [Member]
Debt Instrument [Line Items]
Derivative issuance liability					$ 1,077,756
Loss on derivative liability					$ 539,006
Derivative [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Loss on derivative liability						$ 247,620
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					0
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input						0
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					0.05
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input						0.17
Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares					0.0039
Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares						0.0008
Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares					0.0217
Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares						0.0023
Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					197
Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input						237
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					0.29
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input						1.48
Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares					0.0351
Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares						0.0042
Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares					0.0540
Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares						0.0056
Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					264
Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | Seven Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input						260
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt principal amount	445,500		445,500		$ 572,250	$ 336,500
Proceeds from convertible debt			415,000		538,750	315,000
Debt discount	$ 30,500		$ 30,500		$ 33,500	$ 21,500
Interest rate percentage						12%
Debt maturity date description			January 1, 2023 to September 27, 2023		mature on dates ranging from January 25, 2022, to December 15, 2022	mature on dates ranging from February 3, 2021, to December 17, 2021
Debt conversion description			The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%		The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%	The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 61% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%
Common shares reserve for future issuance | shares	224,973,061		224,973,061
Derivative issuance liability			$ 576,592
Loss on derivative liability			$ 161,592
Common shares reserve, shares | shares					95,273,690	579,347,525
Convertible Promissory Note [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			1 year
Convertible Promissory Note [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0
Convertible Promissory Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate percentage	10%		10%		10%
Convertible Promissory Note [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.48		0.48
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0064		0.0064
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0153		0.0153
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	148		148
Convertible Promissory Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate percentage	12%		12%		12%
Convertible Promissory Note [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.16		4.16
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0143		0.0143
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0272		0.0272
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	216		216
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible notes payable	$ 620,051		$ 620,051
Debt conversion of convertible shares | shares			41,700,228
Gain on derivative liabilities			$ 25,009
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0		0		0
Convertible Notes Payable [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					0.06	0.12
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0063		0.0063		0.0136			0.00055
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.010		0.010		0.022	0.001
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	63		63		125	170
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.51		0.51
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			5 months 8 days		5 months 23 days	25 days
Convertible Notes Payable [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					0.29	0.89
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.016		0.016		0.035	0.0039
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.026		0.026		0.057	0.010
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	191		191		251	305
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.08		4.08
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			6 months		6 months	6 months
Remaining Convertible Notes [Member]
Debt Instrument [Line Items]
Gain on derivative liabilities			$ 233,303
Derivative Liability	$ 392,561		$ 392,561		$ 531,525	$ 437,539
Remaining Convertible Notes [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Gain on derivative liabilities					$ 494,501	$ 206,501
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.013		0.013		0.029	0.0064
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0		0	0
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.05		4.05		0.39	0.12
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0064		0.0064			0.0029
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares					0.0123
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	92		92		165	2.41
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			6 months 7 days		6 months 10 days	9 months 3 days
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares					0.0127
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	158		158		218	2.54
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			11 months 26 days		11 months 15 days	11 months 15 days
Convertible Note [Member]
Debt Instrument [Line Items]
Debt conversion of convertible shares | shares					21,690,671	174,556,025
Debt conversion of convertible shares, value					$ 529,735	$ 262,882
Additional paid in capital on convertible debt features						$ 440,270

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 15, 2020	Jun. 09, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Aug. 09, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate authorized capital			3,505,000,000		3,505,000,000		3,505,000,000
Common stock, shares authorized			3,500,000,000		3,500,000,000		3,500,000,000	3,500,000,000
Common stock, par value			$ 0.001		$ 0.001		$ 0.001	$ 0.001
Preferred stock, shares authorized			5,000,000		5,000,000		5,000,000	5,000,000
Common stock, shares issued			2,588,063,537		2,588,063,537		2,311,123,860	2,233,741,391
Common stock, shares outstanding			2,588,063,537		2,588,063,537		2,311,123,860	2,233,741,391
Preferred stock, shares issued			2		2		0		2
Preferred stock, shares outstanding			2		2		0
Common stock issued for cash				$ 60,000	$ 445,000	$ 285,499	$ 285,499
Common stock issued for conversion of notes			$ 272,919	$ 56,710	$ 943,432	$ 303,159	$ 529,735	$ 262,882
Preferred stock, par value			$ 0.001		$ 0.001		$ 0.001	$ 0.001	$ 0.001
Convertible Notes Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares		18,181,818
Common stock issued for cash		$ 60,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares				1,278,396	44,500,000	4,850,075	4,850,075
Common stock issued for cash				$ 1,278	$ 44,500	$ 4,850	$ 4,850
Common stock issued for conversion of notes, shares			17,532,500	2,835,500	41,700,228	10,499,263	21,690,671	174,556,025
Common stock issued for conversion of notes			$ 17,533	$ 2,836	$ 41,700	$ 10,499	$ 21,691	$ 174,556
Common Stock [Member] | Convertible Notes Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares							21,690,671	174,556,025
Common stock issued for cash							$ 1,019,014	$ 703,152
Common stock issued for conversion of notes, shares					41,700,228		21,690,671
Common stock issued for conversion of notes					$ 595,042		$ 1,019,014
Common Stock [Member] | Land Development [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares					4,000,000		1,500,000
Common stock issued for cash					$ 50,400		$ 58,900
Common Stock [Member] | Salaries [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares					1,034,482		8,341,723	78,681,818
Common stock issued for cash					$ 29,999		$ 239,799	$ 495,900
Common Stock [Member] | License [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares					149,402,390
Common stock issued for cash					$ 3,107,570
Common Stock [Member] | Prepaid fees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares					11,000,000
Common stock issued for cash					$ 242,320
Common Stock [Member] | Consulting Services [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares	20,000,000				25,302,577		21,000,000	173,500,000
Common stock issued for cash	$ 106,000				$ 508,078		$ 858,900	$ 669,750
Common Stock [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares					44,500,000		4,850,075	192,375,737
Common stock issued for cash					$ 445,000		$ 285,500	$ 607,500

Related party transactions (Det

Related party transactions (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 18, 2021	Jun. 17, 2020	Jun. 15, 2020	Jun. 09, 2020	Nov. 30, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction, Rate									0.50%
Common stock issued for cash						$ 60,000	$ 445,000	$ 285,499	$ 285,499
Common Stock [Member]
Common stock issued for cash, shares						1,278,396	44,500,000	4,850,075	4,850,075
Common stock issued for cash						$ 1,278	$ 44,500	$ 4,850	$ 4,850
Common Stock [Member] | Consulting Services [Member]
Common stock issued for cash, shares			20,000,000				25,302,577		21,000,000	173,500,000
Common stock issued for cash			$ 106,000				$ 508,078		$ 858,900	$ 669,750
Convertible Notes Payable [Member]
Common stock issued for cash, shares				18,181,818
Common stock issued for cash				$ 60,000
Convertible Notes Payable [Member] | Common Stock [Member]
Common stock issued for cash, shares									21,690,671	174,556,025
Common stock issued for cash									$ 1,019,014	$ 703,152
Officer [Member]
Accrued Salaries, Current											$ 439,534	$ 663,100
Timothy G Dixon [Member]
Convertible notes payable										$ 60,000
Convertible notes payable interest rate										5%
Three Officers And One Director [Member] | Restricted Stock [Member] | Common Stock [Member]
Common stock issued for cash, shares										122,000,000
Common stock issued for cash										$ 437,400
One Officers And One Director [Member] | Restricted Stock [Member] | Common Stock [Member]
Common stock issued for cash, shares		22,500,000								29,000,000
Common stock issued for cash		$ 154,500								$ 240,000
One Officers [Member] | Restricted Stock [Member] | Common Stock [Member] | Accrued Salaries [Member]
Common stock issued for cash, shares									7,544,848
Common stock issued for cash									$ 239,800
One Officer One Director [Member] | Restricted Stock [Member] | Common Stock [Member]
Common stock issued for cash, shares	2,000,000
Common stock issued for cash	$ 94,600
Four Officer One Director [Member] | Restricted Stock [Member] | Common Stock [Member]
Common stock issued for cash, shares					7,000,000
Common stock issued for cash					$ 224,000

Schedule of Income tax Expense

Schedule of Income tax Expense (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Expected income tax at statutory rate					$ (621,735)	$ (458,619)
State tax					168	168
Meals & Entertainments					295
Permanent differences					404,577	295,578
Other					(71,992)	(336)
Change in valuation allowance					289,487	163,209
Provision for income taxes	$ 800		$ 800		$ 800

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 1,450,896	$ 1,668,324
Valuation allowance	(1,450,896)	(1,668,324)
Net deferred tax asset

Income taxes (Details Narrative

Income taxes (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal and state income taxes rate	30%
Federal net operating loss carryfowards	$ 7.5	$ 6.5
State net operating loss carryfowards	5.5	$ 4.5
Net operating loss carryforwards are available to offset taxable income	$ 5
Net operating loss carryforwards, expiration, description	expires beginning in fiscal 2032

Subsequent events (Details Narr

Subsequent events (Details Narrative) - USD ($)										1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 02, 2022	Oct. 11, 2022	Oct. 07, 2022	Oct. 05, 2022	Feb. 24, 2022	Feb. 14, 2022	Jan. 14, 2022	Jan. 04, 2022	Jun. 15, 2020	Feb. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Conversion of common stock											$ 272,919	$ 56,710	$ 943,432	$ 303,159	$ 529,735	$ 262,882
Common stock issued for cash												$ 60,000	$ 445,000	$ 285,499	$ 285,499
Common Stock [Member]
Subsequent Event [Line Items]
Shares issued for consulting service											9,302,577	5,000,000	25,302,577	8,500,000	21,000,000	173,500,000
Conversion of common stock, shares											17,532,500	2,835,500	41,700,228	10,499,263	21,690,671	174,556,025
Conversion of common stock											$ 17,533	$ 2,836	$ 41,700	$ 10,499	$ 21,691	$ 174,556
Conversion of common stock, shares												1,278,396	44,500,000	4,850,075	4,850,075
Common stock issued for cash												$ 1,278	$ 44,500	$ 4,850	$ 4,850
Common Stock [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares													44,500,000		4,850,075	192,375,737
Common stock issued for cash													$ 445,000		$ 285,500	$ 607,500
Common Stock [Member] | Salaries [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares													1,034,482		8,341,723	78,681,818
Common stock issued for cash													$ 29,999		$ 239,799	$ 495,900
Consulting Services [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares									20,000,000				25,302,577		21,000,000	173,500,000
Common stock issued for cash									$ 106,000				$ 508,078		$ 858,900	$ 669,750
Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion of common stock					$ 15,000,000
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares					149,402,390
Subsequent Event [Member] | Accrued Salaries [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares								1,034,482
Common stock issued for cash								$ 30,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares		8,014,113	5,322,581				4,158,759			4,778,689
Conversion of common stock		$ 49,687.50	$ 33,000				$ 56,975			$ 58,300
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Shares issued price per share					$ 0.01	$ 0.01
Conversion of common stock, shares					10,000,000	24,500,000
Subsequent Event [Member] | Common Stock [Member] | Salaries [Member]
Subsequent Event [Line Items]
Shares issued price per share	$ 0.0099
Conversion of common stock, shares	3,777,777
Subsequent Event [Member] | Consulting Services [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Shares issued for consulting service	3,000,000			110,000
Shares issued price per share	$ 0.0099			$ 0.0122

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
2022	$ 6,249
2022	8,612	$ 26,460
2023		8,911
Total lease payment		35,371
Less: Imputed Interest		(1,187)
Present value of lease liabilities	15,071	34,184
Current portion	(12,918)	(25,374)	$ (24,792)
Non-current portion	$ 2,153	$ 8,810	$ 34,184

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)		9 Months Ended		12 Months Ended
	Mar. 25, 2022 USD ($)	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) ft²	Dec. 31, 2020 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Area of land | ft²				1,700
Lease contract term				36 months
Lease expiration date				Apr. 30, 2023
Payment for rent				$ 22,768	$ 25,993
Operating lease discount rate				5%
Payments to Acquire Intangible Assets		$ 200,000
Assets Transfer and License Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Amortized life of agreement	5 years
Assets Transfer and License Agreement [Member] | Initial Payment [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payments to Acquire Intangible Assets	$ 200,000
Assets Transfer and License Agreement [Member] | Second Payment [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payments to Acquire Intangible Assets	$ 1,800,000
Effective March 1, 2020 [Member] | Lease Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Area of land | ft²		1,700
Lease contract term		36 months
Lease expiration date		Apr. 30, 2023
Payment for rent		$ 18,783
Lease description		The lease will expire in 2023
Operating lease discount rate		5%